AbCellera Biologics, Inc.
(NASDAQ: ABCL)

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

3.597

-0.053 (-1.45%)
Range 3.565 - 3.689   (3.48%)
Open 3.625
Previous Close 3.650
Bid Price 7.010
Bid Volume 11
Ask Price 7.020
Ask Volume 13
Volume 454,106
Value -
Remark
Delayed prices. Updated at 05 Dec 2025 23:06.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis